Amylyx Pharmaceuticals, Inc. (AMLX) is in Healthcare, Drug Manufacturers - Specialty & Generic, based in United States, listed on NasdaqGS. Market cap 3.41B USD. 52-week range 10.83 to 41.14 USD. Data as of 2026-10-09.
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of ...